ZEALAND PHARMA AS
- Country
- 🇩🇰Denmark
- Ownership
- -
- Established
- 1998-01-01
- Employees
- 150
- Market Cap
- $9.1B
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
- Conditions
- OverweightType 2 DiabetesObesity
- Interventions
- Other: Placebo
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 216
- Registration Number
- NCT06926842
- Locations
- 🇺🇸
Cullman Clinical Trials - Family Medicine, Cullman, Alabama, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Medical Investigation Inc, Little Rock, Arkansas, United States
A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide
- Conditions
- Overweight and Obesity
- Interventions
- Drug: Dapiglutide 7.5 mg
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT06758583
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Research Study Looking at the Safety of Single Doses of ZP9830 and How it Works in the Body of Healthy Participants
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT06682975
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 494
- Registration Number
- NCT06662539
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
🇺🇸Innovative Research of West Florida, Inc., Clearwater, Florida, United States
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 84
- Registration Number
- NCT06000891
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 68
- Registration Number
- NCT05613387
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 8
- Registration Number
- NCT05378672
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Indiana University School of Medicine, Indianapolis, Indiana, United States
A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants
- Conditions
- Healthy VolunteersOverweight
- Interventions
- Drug: Placebo (ZP8396)
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 64
- Registration Number
- NCT05096598
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany
The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04991311
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 129
- Registration Number
- NCT04881825
- Locations
- 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸Mayo Clinic College of Medicin, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States